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Background: The study of genetic variants alone is not enough to explain a complex disease like cancer.
Alterations in DNA methylation patterns have been associated with different types of tumor. In order to detect
markers of susceptibility for the development of cutaneous melanoma and breast cancer in the Uruguayan
population, we integrated genetic and epigenetic information of patients and controls.
Methods: We performed two case–control studies that included 49 individuals with sporadic cutaneous melanoma
and 73 unaffected controls, and 179 women with sporadic breast cancer and 209 women controls. We determined
the level of global leukocyte DNA methylation using relative quantification of 5mdC by HPLC, and we compared
methylation levels between cases and controls with nonparametric statistical tests. Since the Uruguayan population
is admixed and both melanoma and breast cancer have very high incidences in Uruguay compared to other
populations, we examined whether individual ancestry influences global leucocyte DNA methylation status. We
carried out a correlation analysis between the percentage of African, European and Native American individual
ancestries, determined using 59 ancestry informative markers, and global DNA methylation in all participants.
Results: We detected global DNA hypomethylation in leukocytes of melanoma and breast cancer patients
compared with healthy controls (p < 0.001). Additionally, we found a negative correlation between African ancestry
and global DNA methylation in cancer patients (p <0.005).
Conclusions: These results support the potential use of global DNA methylation as a biomarker for cancer risk. In
addition, our findings suggest that the ancestral genome structure generated by the admixture process influences
DNA methylation patterns, and underscore the importance of considering genetic ancestry as a modifying factor in
epigenetic association studies in admixed populations such as Latino ones.
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DNA methylation is a critical epigenetic modification of
the genome and is involved in regulating many cellular
processes including gene expression and genomic stability.
Not surprisingly, a growing number of human diseases are
associated with alterations in DNA methylation [1]. De-
regulation of epigenetic modification in tumor DNA such
as hypermethylation of CpG islands at gene promoters
and global reduction of 5-methylcytosine (5mC) levels has
been observed in almost every cancer type [2, 3]. Although* Correspondence: bbertoni@fmed.edu.uy
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specific, recent data indicate that epigenetic traits in white
blood cells are phenotypic markers of genomic instability
and promising candidate risk markers for solid tumors
even after adjusting for known cancer risk factors [4, 5].
There is evidence that ethnic groups differ in terms of
their patterns of DNA methylation in healthy and tumor
tissues [6–10]. Lower global levels of DNA methylation
among healthy middle-aged African American women
relative to European Americans have been reported [6],
and some differences may be already present at birth
[11]. Moreover, the rates of incidence of some epigeneti-
cally influenced diseases, such as cancer, differ amongal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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lifestyles and genetic or epigenetic variants.
For instance, breast cancer incidence varies substantially
across ethnic groups in the US. In addition, genetic ances-
try is associated with breast cancer risk in US Latinas and
Mexican women, where higher European ancestry was as-
sociated with increased risk and higher Native American
ancestry was associated with decreased risk of breast can-
cer [12, 13]. The overall incidence of cutaneous melanoma
has been increasing continuously for the last four decades
in European populations and populations of European
descent [14]. Similarly to breast cancer, European ethnicity
was associated with an increased risk of cutaneous melan-
oma in Brazil [15], and we have previously detected an ex-
cess of European ancestry in Uruguayan melanoma
patients (J.H., unpublished data). Very little has been pub-
lished regarding cutaneous melanoma in other admixed
populations.
The Uruguayan population has been described funda-
mentally as of European origin. However, genetic admix-
ture analysis has shown that it is a tri-hybrid population
with genetic contributions from Native Americans and
Africans as well [16, 17].
Breast cancer is the most common type of cancer
among women in Uruguay. The national incidence rate
is 90.7/100,000 women per year (age-adjusted rates)
[18]. These rates are the highest in Latin America and
resemble those seen in developed Western countries
[19]. The age-adjusted national incidence rates for mel-
anoma are 4.5 and 3.5 per 100.000 in men and women
respectively, and are clearly on the rise since a previous
study conducted in 1996 [20].
Only a few studies have examined the association be-
tween ethnicity and DNA methylation in cancer pa-
tients, all of them were based on self-reported ethnicity
and most investigated DNA methylation changes occur-
ring at tissue level in normal and diseased state [21]. In
order to detect susceptibility markers of sporadic cuta-
neous melanoma and breast cancer in the Uruguayan
population, we examined genetic and epigenetic infor-
mation in melanoma and breast cancer patients and
controls. In particular, we assessed global DNA methyla-
tion in leukocytes of sporadic cancer patients and its as-
sociation with individual genetic ancestry.
Methods
Study population
We performed two case–control studies: 49 individuals
with sporadic cutaneous melanoma and 73 unaffected
controls were recruited at Hospital de Clínicas “Dr.
Manuel Quintela” (Montevideo), and 179 women with
sporadic breast cancer and 209 women controls were
enrolled in different health institutions across Uruguay.
All individuals participating in the breast cancer studywere originally recruited in a previous study described in
Bonilla et al. [22].
In both studies all patients and controls were genetically
unrelated Uruguayans without family history of skin can-
cers, and breast or ovarian cancer, respectively. All breast
cancer patients had been diagnosed a year or less before
inclusion in the study, while melanoma patients were re-
cruited at diagnosis. None of the patients had been sub-
jected to radiotherapy or chemotherapy close to the time
of blood draw. Controls were selected from the same hos-
pitals as patients. Breast cancer controls were women over
35 years of age with a normal mammogram. All partici-
pants in both case–control studies were required to have
a normal hemogram for inclusion in the study.
The procedures followed in both studies were approved
by the ethics committee of the Facultad de Medicina of
the Universidad de la República, Uruguay. After obtaining
written informed consent from all participants of the
study, peripheral blood was drawn for DNA extraction
and participants answered an interview-based question-
naire to record medical and epidemiological information.
Global DNA methylation analysis
We measured global DNA methylation levels in leuko-
cytes through relative quantification of 5-methyl 2′-deoxy-
cytidine (5mdC) using liquid chromatography by HPLC as
detailed elsewhere [23]. Briefly, DNA was hydrolyzed with
nuclease P1 (Sigma-Aldrich) and alkaline phosphatase
(Fermentas-Thermo Scientific) to yield 2′-deoxymononu-
cleosides, which were separated by HPLC and detected by
ultraviolet (UV) light. A mixture of deoxyadenosine, deox-
ythymidine, deoxyguanosine, deoxycytidine, 5-methyl-2′-
deoxycytidine and deoxyuridine (Sigma-Aldrich) was used
as a standard. The percentages of global genomic DNA
methylation were calculated by integration of the 5mdC
peak area (obtained directly from the HPLC) relative to
global cytidine (methylated or not).
A subset of 49 melanoma patients and 60 unaffected
controls, and 95 breast cancer patients and 95 unaffected
women were analyzed by HPLC in duplicate. The average
for each sample was calculated. Duplicated samples show-
ing a difference in 5mdC greater than 3 % or with low
HPLC resolution were removed.
Genotyping and Individual admixture analysis
The ancestry informative markers (AIMs) used in this
study were 59 biallelic single nucleotide polymorphisms
(SNPs) (Additional file 1: Table S1) selected from the AIMs
panel for Hispanic populations described by Fejerman
et al. [12] which show a large difference in allele frequency
between ancestral populations (>0.5). The AIMs are spaced
along the 22 autosomes to assure balanced ancestry infor-
mation. The AIMs were genotyped by the KASPar SNP
Genotyping System (Kbiosciences Ltd, UK). Individual
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Chain Monte Carlo algorithm implemented in STRUC-
TURE 2.3.4 [24]. Given the trihybrid parental contribu-
tion (European, African and Native American) to the
Uruguayan population the program was run mainly with
K = 3, but also with K = 2 due to the African contribu-
tion being quite low, as the predefined setting for the
number of ancestral populations, with 10,000 iterations
for the burn-in period and 50,000 additional iterations
to obtain parameter estimates. In all cases the program was
instructed to use parental population information. Several
options were explored, such as the admixture and linkage
models, and independent or correlated allele frequencies, to
uncover changes in the clustering pattern. The AIMs data
from parental populations used to estimate admixture pro-
portions included 42 Europeans, 37 West Africans, and 30
Native Americans (15 Mayans and 15 Nahuas), which were
genotyped on an Affymetrix 100K SNP chip (data kindly
provided by Dr. Laura Fejerman, UCSF).
In order to test for association of genes involved in
DNA methylation with global DNA methylation, we geno-
typed SNPs in MTHFR (C677T rs1801131), DNMT3A
(rs4665777), DNMT3B (rs406193) and BRCA1 (rs16942,
rs1799950, rs176092, rs8176193) in all breast cancer cases
and controls with methylation level data.
We analyzed methylation levels around each AIM in
populations closely related to the parental populations of
the Uruguayan samples to better understand the relation-
ship between ancestry and global DNA methylation.
Methylation data was obtained from 96 African Americans
(AA), 96 Caucasian Americans (CA) and 96 Han Chinese
Americans (HC), used in the Heyn et al. study [7]. A
window of 100kb surrounding each AIM was analyzed,
the average methylation status was calculated for the
whole window and also for promoters, gene bodies and
intergenic regions.
Statistical analysis
Shapiro-Wilks test was used to test for normality of the
methylation data. Because methylation data were not nor-
mally distributed, we used nonparametric tests in the stat-
istical analyses. We applied the Mann–Whitney-Wilcoxon
test to identify differences between affected and control
individuals in binary variables or the Kruskall-Wallis test
for variables with more than two states. The epidemiologic
variables analyzed are shown in Additional file 2: Table S2.
We also used logistic regression to examine the associ-
ation of methylation data with disease, adjusted by age
and ancestry. To evaluate the effect of potential con-
founders of the association between global DNA methy-
lation and cancer, we examined the association of
disease status with age, smoking status, body mass index
(BMI) and genetic variants associated to epigenetic pro-
cesses in breast cancer study. BMI and smoking statusare not considered risk factors for melanoma in the lit-
erature, so we measured only age and gender as a con-
founders in our sample.
The association between DNA methylation and individual
ancestry was assessed with the Kendall rank correlation test.
To visualize the relationship between individual ancestry
and DNA methylation we used a classification and regres-
sion tree [25]. We performed all statistical analyses using the
R environment for statistical computing version 2.15.3 [26].
Results
We measured global genomic methylation levels in leuko-
cytes through relative quantification of 5mdC in cutane-
ous melanoma and breast cancer patients and unaffected
control individuals. We obtained global DNA methylation
data for 42 melanoma patients and 46 controls as well as
for 86 breast cancer patients and 92 controls (data avail-
able in Additional files 3 and 4).
In both case–control studies performed, we found a
significant difference in global leukocyte DNA methyla-
tion between individuals with cancer and unaffected
controls (p < 0.001; Table 1). The average methylation
levels in melanoma and breast cancer patients were
lower (2.54 ± 0.37 % and 2.33 ± 0.48 %, respectively) than
the average methylation levels in unaffected controls
(2.79 ± 0.27 and 2.77 ± 0.77 %, respectively), (Table 1 and
Additional file 5: Figure S1). We found evidence of a dif-
ference in age between cases and controls (Additional
file 2: Table S2). Therefore, we analyzed the correlation
between global DNA methylation levels and age in both
the melanoma and the breast cancer studies and did not
detect a significant association (Table 2). No other asso-
ciations with confounding factors were uncovered for
cancer status or global DNA methylation (Table 1 and
Additional file 2: Table S2). We did not detect an associ-
ation between genetic variants directly or indirectly
involved in epigenetic processes such as C677T in
MTHFR, rs4665777 in DNMT3A, rs406193 in DNMT3B,
rs16942, rs1799950, rs8176092, rs8176193in BRCA1,
and global DNA methylation levels in the breast cancer
study (p > 0.05 for all, Additional file 6: Table S3).
In order to determine the degree of admixture of all sub-
jects, we analyzed a set of 59 SNPs that can identify Native
American, African, and European ancestry (Additional file
1: Table S1). In the admixture analysis, we first studied the
ancestry distribution among individuals, and there was no
significant difference in the ancestral individual contribu-
tions between melanoma patients and unaffected controls.
The same was found in the breast cancer case–control
study (Table 1). However, we detected higher percentages
of European ancestral contribution in the melanoma
case–control study than in the breast cancer study. The
differences between the two case–control studies may be
attributable to differences in sampling locations. We
Table 1 Average global DNA methylation and ancestral contributions in melanoma and breast cancer cases and controls
N Cases N Controls P value
Global DNA methylation (±SD)
Melanomaa 42 2.54 ± 0.37 % 46 2.79 ± 0.27 % 9.96e−4
Breast cancera 86 2.33 ± 0.48 % 92 2.77 ± 0.77 % 5.96e−5
Global DNA methylation-Gender
Melanoma
Female 22 2.48 ± 0.42 % 29 2.79 ± 0.24 % 0.269b
Male 20 2.63 ± 0.30 % 17 2.80 ± 0.32 % 0.198c
Ancestry (±SD)
Melanoma 49 73
European 95.04 ± 6.48 % 93.32 ± 11.39 % 0.184
Native American 3.33 ± 5.81 % 4.94 ± 7.71 % 0.211
African 1.16 ± 3.37 % 1.74 ± 4.84 % 0.120
Breast cancer 179 209
European 76.89 ± 12.95 % 76.49 ± 14.26 % 0.927
Native American 12.86 ± 10.46 % 13.85 ± 11.37 % 0.229
African 10.25 ± 8.30 % 9.66 ± 7.55 % 0.420
aLogistic regression for Melanoma P = 7.10e−4 and Breast cancer P = 5.47e−4, adjusted by ancestry and age
bComparison between females and males in cases.
cComparison between females and males in controls
Cappetta et al. BMC Cancer  (2015) 15:434 Page 4 of 8performed a logistic regression of global DNA methyla-
tion and disease status adjusted by ancestry and age to
avoid confounder effects and we found that the associ-
ation was still significant for melanoma and breast can-
cer (P = 7.10e-4 and P = 5.47e-4 respectively; Table 1).
To ascertain whether individual ancestry is influencing
the global DNA methylation status in leukocytes, we car-
ried out a correlation analysis between the percentage of
African, European and Native American individual contri-
butions and global DNA methylation. As shown in Table 2,




Cases 41 −0.140 28
Controls 45 −0.034 39
Breast cancer 169 −0.028
Cases 80 −0.008 78
Controls 89 0.064 89
Total samples
Cases 121 −0.049 106
Controls 134 0.072 128
aIndividuals with DNA methylation data but without age and/or ancestry data were
bp < 0.01
cp < 0.005association between the African ancestral component and
the percentage of global DNA leukocyte methylation in
breast cancer patients (τ = −0.199, p < 0.01). We did not
observe a significant association between methylation and
genetic ancestry in melanoma patients probably due to
the reduced numbers of participants without missing data.
However, when considering all melanoma and breast can-
cer patients together, the negative correlation with the
African ancestral component became statistically stronger
(τ = −0.187 p < 0.005, Table 2 and Additional file 7: Figure
S2a). A significant positive correlation with the Europeanleukocyte global DNA methylation and ancestral components







removed from this analysis
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Additional file 7: Figure S2b). In contrast, we could not
detect any correlation between DNA methylation level
and genetic ancestry in unaffected controls.
The relationship between the AIMs and methylation sta-
tus was analyzed in AA, CA and HC populations. The
methylation level in intergenic regions shows statistically
significant differences between these 3 populations (Table 3).
Average DNA methylation in gene bodies and promoter re-
gions in the CA population also exhibits differences with
respect to AA and HC. The average DNA methylation
levels of CpG sites in a ±100 kb flanking region for each
AIM shows that 27 of 48 AIMs are different between at
least two populations (Additional file 8: Table S4).
A clearer image of the relationship between ancestry
and global methylation was obtained using a classifica-
tion and regression tree of disease status on DNA
methylation, adjusted by age. The tree shows the pre-
dictive values or averages of DNA methylation according
to the proportion of African and European ancestry in
each patient (Fig. 1). The higher the African genetic in-
dividual component in patients, the lower the percentage
of DNA leukocyte methylation detected.Discussion
There is growing evidence that leukocyte DNA methyla-
tion status is associated with cancer [4, 5]. The potential
causes of this association include environmental and
genetic factors. In the present work, we investigated
whether genetic ancestry plays a role on the patterning
of global DNA methylation.
We have uncovered evidence of global DNA hypome-
thylation in leukocytes of cancer patients and of a nega-
tive correlation between African genetic individual
ancestry and leucocyte methylation among sporadic can-
cer patients from an admixed population. Previous stud-
ies have identified differences in DNA methylation
between ethnic groups, regardless of disease status [6–8,
10, 11]. But in all of these studies ethnicity was self-
reported. To the best of our knowledge no other studies
have examined the relationship between individualTable 3 Mean difference in CpG methylation in a ±100 kb
window flanking ancestry informative markers (AIMs) between
African-Americans (AA), Caucasian-Americans (CA) and Han
Chinese-Americans (HC), according to gene context
Gene Context Mean β value P value*
AA CA HC AA_CA AA_HC CA_HC
Gene body 0.520 0.497 0.523 4.85e−6 3.56e−1 4.20e−8
Intergenic region 0.584 0.552 0.594 2.81e−17 2.48e−3 4.24e−31
Promoter 0.304 0.292 0.306 1.92e−2 6.72e−2 2.77e−5
*Wilcoxon Rank Sum test, FDR p-valuegenetic ancestry, calculated using AIMs, on global
leukocyte DNA methylation.
Genomic DNA hypomethylation is believed to have an
important impact on tumor biology through the generation
of chromosomal instability, reactivation of transposable el-
ements, and loss of imprinting [27]. Thus, an association
between genomic hypomethylation and cancer was ex-
pected. There is increasing evidence that leukocytes may
be a useful cell model to evaluate epigenetic changes.
Epimutations and global DNA hypomethylation, associ-
ated with increased cancer risk could be detected in periph-
eral blood, instead of the affected tissue [5]. This is
important since blood samples are much easier to obtain
and can be used for large-scale epidemiological studies [28].
We report a significant association of global leukocyte
DNA hypomethylation with sporadic cutaneous melan-
oma. This result is in contrast to a previous study, carried
out in melanoma-prone families, which found no signifi-
cant association between overall or CpG site-specific
LINE-1 methylation in peripheral blood and cutaneous
melanoma [29]. However, there are two important differ-
ences between the studies. First, the methylation levels of
one repetitive LINE-1 element do not necessarily repre-
sent 5mdC content across the whole genome. And second,
the study by Hyland et al. examined the association be-
tween DNA methylation and familial cutaneous melan-
oma, suggesting that in this case the genetic mechanism
was more important than the epigenetic effect. On the
other hand, we corroborated earlier findings of an associ-
ation of leucocyte DNA hypomethylation with breast can-
cer risk [30]. The level of global DNA methylation found
in our study is slightly lower than some previous studies
reported. However, the overall level of DNA methylation in
blood samples varies substantially (2.3 to 6 %) depending
on the protocols used, the disease considered, the age
range and a number of environmental factors [31–36].
Therefore, the challenge to use global hypomethylation as
a clinical marker in cancer will be to define and standardize
methodologies for its determination in large numbers of
patients.
Growing evidence shows that global DNA methylation,
particularly in blood, changes with age, gender, BMI, and
lifestyle factors, such as diet and smoking [37, 38]. How-
ever, global methylation levels were not associated with
any of the epidemiologic variables examined in our study.
At the population level, the incidence rates of some
complex diseases like cancer vary between populations
from different continents, probably as a result of adapta-
tion to local selective factors but also as a result of genetic
ancestry. Ethnic differences in breast cancer and cutane-
ous melanoma incidence are well documented and in both
cases European descendants show higher rates with re-
spect to other geographic populations [18]. Therefore, the
trihybrid genetic structure of the Uruguayan population is
Fig. 1 Regression tree analysis of leukocyte global DNA methylation and ancestry in cancer patients. Ancestry is shown as a frequency, and predictive
global DNA methylation percentages are shown at the end of the branches.
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components on disease. It has been recently reported that
slight ethnic differences exist at birth among specific
CpGs, and the predominant pattern is of lower levels of
CpG methylation among African Americans [11]. Then,
the negative correlation between African ancestry and glo-
bal genomic methylation in leukocytes of cancer patients
found in the present study is in agreement with the exist-
ing literature. Since we observed no differences between
patients and controls with respect to individual genetic
ancestry, DNA hypomethylation in patients cannot be at-
tributed to differences in genetic ancestry between groups.
When analyzing CpGs surrounding the AIMs we ob-
served a significant difference between CA and other pop-
ulations (i.e. AA and HC). It has been demonstrated that
methylation levels at individual CpG sites can be strongly
associated with both local and distant sequence variation
[39, 40]. SNP allele frequencies can differ substantially
among populations with different geographic ancestries
[41], which suggest that ethnic differences in DNA methy-
lation could be due to differences in population specific al-
leles or haplotypes that influence CpG and global
methylation levels. It seems that even though there is no
ancestry difference between patients and controls, the
former have exclusive African sequences associated with
hypomethylation. Consequently, the individual geneticancestry may contribute to the inter-individual variation
of global DNA methylation among cancer patients.
Fraser et al. [42] suggested that DNA methylation is
highly divergent between populations, and that this di-
vergence may be in large part due to a combination of
differences in allele frequencies and complex epistasis or
gene-environment interactions. Thus, a variant that is
present in two populations could affect DNA methyla-
tion in only one. Moreover, Heyn et al. [7] identified
DNA methylation differences that distinguish three
major human ethnic groups (Caucasian-American,
African-American and Han Chinese-American) and
CpG methylation quantitative trait loci associated with
natural human variation, contributing to the diverse
phenotypic characteristics of human populations.
There is limited data available on DNA methylation in
worldwide populations. Even though the Han Chinese is
not strictly a parental population to modern Uruguayans,
it is the closest to Native Americans we can get with data
available for both the AIMs (HapMap) and CpG methyla-
tion status [7]. Since we wanted to explore the relationship
between the AIMs and the methylation status of CpGs
surrounding the AIMs in the parental populations, we
used the Han Chinese as a proxy for Native Americans.
The genetic distance between East Asians and Native
Americans is smaller than between Africans or Europeans
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DNA methylation levels reported by Heyn et al. [7] and
our analysis of their data, between African Americans,
Caucasian Americans and Han Chinese, suggest that there
may also exist differences between the Uruguayan parental
populations. Therefore, the tri-hybrid structure of the
admixed Uruguayan population could partially explain the
methylation pattern. The African genetic ancestry may
play a particular role in the susceptibility to or etiology of
these cancers, not necessarily in the same way as in other
regions of the world.
These results should be confirmed in large cohort
studies, given the relatively small sample size of our
case–control groups, as well as in other admixed popu-
lations. We had no data on cancer staging or tumor
grade, so additional studies are required to clarify if the
influence of individual genetic ancestry on DNA methy-
lation levels affects tumor aggressiveness or outcome in
patients with different ancestral components.
Conclusions
In conclusion, our findings suggest that individual genetic
ancestry influences global leukocyte DNA methylation
level in cancer patients of Uruguay. These findings high-
light the importance of taking into account individual gen-
etic ancestry when examining epigenetic data in Latin
American populations. Most importantly, the possibility
that genetic ancestry could be associated to methylation
or demethylation-prone chromosomal regions indicates
that the admixture gene mapping technique [44] could be
extended to relate ancestral chromosomal segments, epi-
genetic status and susceptibility to disease. Thus, the
prevalence of epigenetic alterations may provide a basis
for understanding the unequal cancer burden of disease
early onset, aggressiveness, and poor outcomes experi-
enced by individuals of different ethnicities.
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